K050084

**General Device Summary** 

Device:

Cosman RF Lesion Generator, Model RFG-1A, and

associated Radiofrequency Lesion Probes

Proprietary Trade Name:

Cosman RF Lesion Generator, Model RFG-1A

Cosman Radiofrequency Lesion Probes

Manufacturer:

Cosman Medical, Inc.

76 Cambridge St., Burlington MA 01803. USA

Tel. 781-272-6561. Fax 781-272-6563

Contact Name:

Michael Arnold, Director of RA/QA email: marnold@cosmancompany.com

Establishment Registration No.:

Number not assigned

Sterilization Site Address:

No part of this device is supplied sterile.

Classification:

882.4400, Radiofrequency Lesion Generator, Class II

Neurology Devices, Product Code: GXD

882,4725, Radiofrequency Lesion Probe, Class II

Neurology Devices, Product Code: GXI

Performance Standard:

No applicable performance standards have been issued

under section 514 or under section 513(b) of the Food,

Drug, and Cosmetic Act.

Predicate Devices:

Radionics RFG-3C Plus Lesion Generator (K982489)

Radionics SMK Sluiter-Mehta Kit (K870028,

K963577 K980430 and Preamendment Devices)

Radionics Microelectrode Kit (K991399)

Diros Technology URF-2AP Lesion Generator (K021869) Diros Technology URP-2A and Associated Radiofrequency

Probes (K010202)

Intended Use: The Cosman RF Lesion Generator, Model RFG-1A, and associated Radiofrequency Lesion Probes, is indicated for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures.

Device Equivalence: The Cosman RF Lesion Generator, Model RFG-1A, and associated Radiofrequency Lesion Probes have been compared to previously 510(k) cleared devices with respect to intended use and technological characteristics. Performance testing was done to

Page 2 80

results in this 510(k) notification show that the Cosman RF Lesion Generator, Model RFG-1A, and associated Radiofrequency Lesion Probes are substantially equivalent to predicate devices and are safe and effective for their intended use.





MAR 1 7 2005

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Michael Arnold Director of RA/QA Cosman Medical, Inc. 76 Cambridge Street Burlington, Massachusetts 01803

Re: K050084

Trade/Device Name: Cosman RF Lesion Generator, Model RFG-1A

Cosman Radiofrequency Lesion Probes

Regulation Number: 21 CFR 882.4725

Regulation Name: Radiofrequency lesion probe

Regulatory Class: II Product Code: GXI, GXD Dated: January 11, 2005 Received: January 13, 2005

Dear Mr. Arnold:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

## Page 2 - Mr. Michael Arnold

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Ge Miriam C. Provost, Ph.D.

Acting Director

Division of General, Restorative and Neurological Devices
Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## **Indications for Use**

510(k) Number (if known): <u>K050084</u>
Device Name: Cosman RF Lesion Generator, Model RFG-1A and associated Radiofrequency Lesion Probes
Indications For Use:
"The Cosman Radiofrequency Lesion Generator, Model RFG-1A, and associated Radiofrequency Lesion Probes, is indicated for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures."
Prescription Use X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE) Page 1 of

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number K050084